News | December 26, 2023
AstraZeneca to acquire China's Gracell Biotechnologies for US $1.2 billion
Furthering cell therapy ambition across oncology and autoimmune diseases
Furthering cell therapy ambition across oncology and autoimmune diseases
The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F
Subscribe To Our Newsletter & Stay Updated